Therapeutic Area

Not specified

Therapeutic area intelligence for Not specified with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 4
Catalysts: 4
Companies: 4

Companies

Alembic Pharmaceuticals →

AstraZeneca →

Bayer Healthcare Pharmaceuticals →

TEVA PHARMACEUTICALS, INC →

Assets

Recent signals(4)

RegulatoryJune 18, 2026

Bayer's NDA219627 Receives Approval from FDA

Bayer Healthcare Pharmaceuticals has received approval for NDA219627 from the FDA.

StrategyJune 18, 2026

Alembic Pharmaceuticals Submits ANDA220639 for Review

Alembic Pharmaceuticals has submitted ANDA220639 for review with a standard review priority.

RegulatoryJune 18, 2026

TEVA Pharmaceuticals submits ANDA219413 for FDA review

TEVA Pharmaceuticals has submitted ANDA219413 to the FDA with a standard review priority.

StrategyJune 16, 2026

AstraZeneca Reports Strong Q1 2026 Revenue Growth and Positive NME Readouts

AstraZeneca reported a 13% increase in total revenue for Q1 2026, driven by strong product sales and positive readouts from new molecular entities (NMEs).

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.